Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
datopotamab deruxtecan + pembrolizumab
- Development stage
- Phase 3
- Lead developer
- Daiichi Sankyo
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Datopotamab deruxtecan + pembrolizumab is an investigational combination therapy consisting of an antibody-drug conjugate (datopotamab deruxtecan) and an immune checkpoint inhibitor (pembrolizumab). Datopotamab deruxtecan (Dato-DXd) is composed of a humanized anti-TROP2 monoclonal antibody linked to a potent topoisomerase I inhibitor payload via a tetrapeptide-based linker. Once bound to TROP2 on cancer cells, the conjugate is internalized, and the payload is released in lysosomal compartments, causing DNA damage and triggering cellular apoptosis. Pembrolizumab is an anti-PD-1 monoclonal antibody that enhances T-cell immune responses against tumor cells. The combination is being evaluated in several Phase 3 clinical trials for non-small cell lung cancer (NSCLC), with early data showing promising efficacy and manageable safety profile.
- Other names
- Datopotamab deruxtecan plus pembrolizumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TACSTD2 (Tumor-associated calcium signal transducer 2)
Beyond the preview
Go deeper on datopotamab deruxtecan + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on datopotamab deruxtecan + pembrolizumab.